Corbus Pharmaceuticals (CRBP) AI Stock Analysis

• Market Cap: $76.45M
• Dividend Yield: N/A
• Average Volume (3M): 179.91K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.74
• Revenue Growth: N/A
• EPS Growth: 64.71%
• Country: US
• Employees: 28
• Sector: Healthcare
• Sector Strength: 60
• Industry: Biotechnology
• EPS (TTM): -1.39
• Shares Outstanding: 12,232,228
• 10 Day Avg. Volume: 161,115
• 30 Day Avg. Volume: 179,913
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.86
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $47.14
• Price Target Upside: 669.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

Corbus Pharmaceuticals' overall stock score is driven by severe financial challenges, including no recent revenue and high net losses, which significantly weigh down its score. However, technical indicators suggest some short-term positive momentum. The promising Phase 1 trial results provide a potential catalyst in the biotechnology field, offering some positive outlook despite the current financial difficulties.

Positive Factors

Clinical Trial Results

Corbus reported an objective response rate of 57% among head and neck squamous cell carcinoma patients treated with CRB-701, showing promising results in its clinical trial.

Financial Position

The company ended the quarter with $132.8 million in cash, cash equivalents, and investments, providing a strong financial position.

Regulatory Approval

The FDA has granted CRB-701 Fast Track designation in relapsed/refractory metastatic cervical cancer, supporting its emergence as a strong contender in the ADC space.

Negative Factors

Market Valuation

Given the sustained multiple compression across SMID-cap biotech, the valuation framework is adjusted to reflect a more risk-averse market environment, including lowering P/E multiples and increasing discount rates.

R&D Spending

Higher-than-expected costs associated with study initiations drove the increased R&D spending during the quarter.

Short Interest

The company has a high short interest of 20.3%, indicating that a significant portion of investors are betting against the stock.

Corbus Pharmaceuticals Business Overview & Revenue Model

Company Description

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a clinical-stage pharmaceutical company specializing in the development and commercialization of novel therapeutics for the treatment of inflammatory and fibrotic diseases. The company's primary focus is on harnessing the potential of the endocannabinoid system to develop drugs that address chronic diseases with significant unmet medical needs. Corbus is engaged in developing a pipeline of innovative drug candidates targeting these conditions, with a particular emphasis on rare inflammatory diseases.

How the Company Makes Money

Corbus Pharmaceuticals primarily makes money through the development and commercialization of its drug candidates. The company's revenue model involves advancing its drug pipeline through clinical trials, obtaining regulatory approvals, and subsequently partnering with larger pharmaceutical companies for distribution and commercialization. Key revenue streams include milestone payments from strategic partnerships, licensing agreements, and potential sales of its proprietary drugs once approved. Corbus relies on collaborations with other pharmaceutical companies and research institutions to enhance its research capabilities and expedite the development of its therapeutic candidates, which is crucial for generating future revenue.

Corbus Pharmaceuticals Financial Statement Overview

Summary

Corbus Pharmaceuticals faces severe financial challenges with no revenue in recent periods, high net losses, and cash flow issues. The balance sheet shows some recovery in equity, but financial instability remains a risk. Strategic changes are essential for financial health improvement.

Income Statement

Corbus Pharmaceuticals has faced significant revenue challenges, with zero revenue in recent years and declining gross profit margins. The company's net losses have been substantial, indicating ongoing operational struggles. While total revenue was positive in 2019, it has since dropped to zero, highlighting critical revenue generation issues.

Balance Sheet

The company's financial stability is concerning, with a significant debt load relative to equity, although the debt-to-equity ratio improved in 2024 due to positive equity. The equity ratio shows weak equity backing, but the positive stockholders' equity in 2024 is a recovery sign from previous negative equity.

Cash Flow

Corbus Pharmaceuticals has consistently experienced negative operating and free cash flows, indicating cash burn without adequate inflows from operations. The free cash flow to net income ratio is negative, reflecting inefficient cash usage. However, financing inflows in 2024 improved cash positions, providing temporary relief.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	881.71K	3.94M
	Gross Profit
0.00	-31.17M	-1.49M	-757.53K	3.84M
	EBIT
0.00	-45.08M	-39.84M	-55.99M	-122.81M
	EBITDA
0.00	-44.44M	-38.73M	-54.97M	-121.69M
	Net Income Common Stockholders
-40.21M	-44.60M	-55.83M	-45.55M	-111.30M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
149.06M	20.91M	59.20M	97.65M	85.43M
	Total Assets
155.88M	28.27M	66.31M	107.73M	102.29M
	Total Debt
3.24M	20.88M	25.09M	26.59M	26.84M
	Net Debt
-13.96M	7.16M	8.09M	1.58M	-58.60M
	Total Liabilities
13.45M	35.18M	33.32M	38.62M	57.02M
	Stockholders Equity
142.43M	-6.90M	32.99M	69.11M	45.27M
Cash Flow		Free Cash Flow
-41.79M	-36.10M	-37.56M	-48.24M	-100.17M
	Operating Cash Flow
-41.79M	-36.10M	-37.54M	-48.18M	-99.69M
	Investing Cash Flow
-121.31M	35.64M	30.07M	-73.42M	-484.49K
	Financing Cash Flow
166.58M	-2.82M	-533.62K	60.82M	154.87M

Corbus Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.13
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBP, the sentiment is Negative. The current price of 6.13 is below the 20-day moving average (MA) of 6.76, below the 50-day MA of 6.44, and below the 200-day MA of 21.46, indicating a bearish trend. The MACD of 0.17 indicates Positive momentum. The RSI at 43.00 is Neutral, neither overbought nor oversold. The STOCH value of 11.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRBP.

Corbus Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XGN	60 Neutral	$115.58M	―	-117.50%	―	1.78%	22.46%
Sector *	52 Neutral	$5.24B	3.76	-41.88%	2.85%	17.01%	0.78%
ASRT	48 Neutral	$58.42M	―	-16.66%	―	-17.83%	94.26%
PYXS	47 Neutral	$66.28M	―	-62.75%	―	―	30.51%
CRBP	43 Neutral	$76.45M	―	-44.89%	―	―	64.71%
ACRV	36 Underperform	$41.70M	―	-54.07%	―	―	10.84%
ACET	27 Underperform	$49.86M	―	-55.83%	―	―	59.75%

Corbus Pharmaceuticals Corporate Events

Corbus Pharmaceuticals Announces Board Member Departure

On March 20, 2025, Dr. Peter Salzmann informed Corbus Pharmaceuticals Holdings, Inc. that he will not seek re-election to the Board of Directors at the 2025 annual meeting. Dr. Salzmann will continue his role until the meeting, and his decision was not due to any disagreements with the company. Consequently, the Board will reduce its size from eight to seven members after the meeting.

Corbus Pharmaceuticals Appoints Ian Hodgson as COO

On March 13, 2025, Corbus Pharmaceuticals appointed Ian Hodgson as Chief Operating Officer, effective March 15, 2025. Hodgson, with over 25 years of experience in drug development, previously served as Head of Operations at Corbus and has held various leadership roles in the biotech and pharmaceutical sectors. His appointment is accompanied by a Service Agreement that outlines his compensation and employment terms, including non-compete clauses and provisions for termination under specific circumstances.

Corbus Pharmaceuticals Reports Q4 2024 Financial Results

Corbus Pharmaceuticals reported its Q4 and 2024 financial results, highlighting significant progress in its oncology and obesity programs. The company announced encouraging Phase 1 results for CRB-701 in Western studies, with the FDA granting Fast Track designation for its use in metastatic cervical cancer. The company also plans to start a study for CRB-913 in March 2025. Financially, Corbus reported a net loss of $9.5 million for Q4 2024, with $149 million in cash and investments, expected to fund operations through Q3 2027.

Corbus Pharmaceuticals Reports Promising Phase 1 Trial Results

On February 14, 2025, Corbus Pharmaceuticals announced data from a Phase 1 clinical trial for CRB-701, presented at the ASCO GU Symposium. The trial in the US and UK showed promising safety and efficacy, with no dose-limiting toxicities and encouraging responses in several tumor types, including a first-time exploration in head and neck squamous cell carcinoma. This positions Corbus strongly within the oncology field, potentially impacting stakeholders positively.